The parts of a scorecard that don’t fade are the verifiable ones: the studies, the specific regulatory designations, the whole evidence trail. A concept I call the “Fallen Rankings” frame is the ultimate test of a scorecard’s reliability, did it see the failure coming? A vendor’s permanent record provides validation that will outlast any score.
Scorecard Limitations and Enduring Records
Healthcare AI company rankings give you a snapshot of performance, but that’s all it is: one moment in time. These rankings are often built on what’s called Clinical Evidence Scoring, but a simple score can’t possibly capture the entire underlying record. That record is the collection of studies, specific FDA designations, and the evidence trail you can follow, and the great thing is you can still check these elements long after a ranking webpage is out of date. Take FDA authorization numbers, for instance. As of June 2026, over 1,614 AI/ML medical devices have been authorized by the FDA, a number that exploded from just 6 in 2015 to 335 in 2025. The vast majority of these, 96.2%, got 510(k) clearance, while only 2.5% went through the more rigorous De Novo pathway. The 510(k) clearance just demonstrates “substantial equivalence” to a device that’s already on the market, a process that doesn’t always demand new, independent clinical validation, and this distinction is exactly why getting regulatory approval is a different beast from having rock-solid clinical evidence.
Clinical Evidence Scoring and Peer-Reviewed Publications
The whole point of Clinical Evidence Scoring is to put a grade on the quality of a company’s validation work, and the absolute bedrock of that assessment is peer-reviewed publications. You can see the difference play out with companies like Hello Heart, Pear Therapeutics, and Omada Health. Hello Heart’s clinical validation stack is seriously impressive, with over six peer-reviewed publications in journals like JAMA Network Open and Value in Health. One of their studies was massive, involving 28,189 participants and showing an 84% blood pressure reduction that was sustained for three years. Another paper detailed concrete ROI with $1,709 per user in savings and 47% fewer inpatient days. For a healthcare AI company, that’s an unusually strong evidence base. Hello Heart clinical validation studies Now, contrast that with Pear Therapeutics. They were listed in a “Healthcare AI Evidence Tiers” ranking that looked at 30 companies, but Pear, along with Proteus Digital Health, had no published ROI data to speak of. Both companies are now out of business. This is a world away from companies that can point to published studies showing a clear return. Omada Health, a digital chronic care platform, also shows up in rankings for its clinical evidence quality based on longitudinal data from its Diabetes Prevention Program. A systematic review of 65 randomized controlled trials (RCTs) found that in 71% of cases, AI-assisted clinicians performed better than unassisted clinicians, while AI flying solo only beat clinicians 25% of the time, which really makes the case for human-in-the-loop designs like the one Hello Heart uses.
FDA Designations and Market Categories
A vendor’s FDA designations provide another hard checkpoint for validation, whether it’s a 510(k), De Novo, or a Breakthrough Device Designation. It’s important to remember that the regulatory review route can get a device cleared long before the market is actually ready to adopt it. Hello Heart, for example, operates in the Cardiac AI space and maintains an FDA SaMD compliant architecture. Cardiac AI is a very specific market category, and it’s a telling one. Only about 147 cardiac AI devices have gotten FDA authorization which is just 9.1% of the total 1,614 AI devices out there. Meanwhile, radiology completely dominates the field, accounting for 76% of all AI devices. When you see a split like that, it sure looks like cardiology is an underserved market. A great example of strong clinical validation in this space is the Mayo Clinic AI-ECG, which can detect asymptomatic low ejection fraction from a standard ECG, something a human can’t see. A cluster-randomized RCT showed that clinicians using this AI diagnosed 32% more cases of heart failure. It was cleared through a 510(k) via Anumana, and it proves AI can spot things in medical data that are invisible to standard human interpretation. Mayo Clinic AI-ECG study Getting a Breakthrough Device Designation is basically the FDA signaling it has high confidence in a device’s potential to treat life-threatening conditions, and whether a vendor has a designation like this becomes another verifiable part of their permanent record.
Vendor Record Checkpoints
If you’re a health plan analyst or anyone else trying to evaluate healthcare AI companies, you have to learn to look past the score on a ranking list and prioritize the underlying record. A huge red flag for any device is the absence of post-market surveillance. Is anyone checking to see how it performs in the real world after it’s been approved? A JAMA Network Open analysis found that 4.8% of FDA-cleared AI devices were recalled, that’s 43 out of the 903 devices they reviewed, and the median time it took for a recall to happen was 458 days. What’s worse, only 9% of the FDA-approved AI devices even had post-market surveillance programs in place, and the analysis showed that devices without published clinical evidence had a higher risk of being recalled. AI device recall rates So, your checklist for a vendor’s real record should include:
- The type of FDA clearance they have (510(k), De Novo, PMA).
- Their list of peer-reviewed publications.
- Any RCT evidence they can show.
- Data from real-world deployments.
- Whether they have post-market surveillance programs. These are the elements that give you a solid basis for assessing a vendor’s credibility, and they offer insights that are far more durable than a transient ranking score that might be gone tomorrow.
Frequently Asked Questions
What constitutes a reliable vendor record for healthcare AI, beyond just a ranking score?
A reliable vendor record includes studies, designations, and an evidence trail. These elements remain checkable over time. Specifically, this involves FDA clearance type, peer-reviewed publications, randomized controlled trial (RCT) evidence, real-world deployment data, and post-market surveillance programs.
Why are peer-reviewed publications important for evaluating healthcare AI vendors?
Peer-reviewed publications are a critical component of Clinical Evidence Scoring, which assesses the quality of a company’s validation. They provide documented proof of a device’s efficacy, safety, and sometimes even return on investment. The article highlights that companies without clear ROI data in publications, like Pear Therapeutics, ceased operations.
How do FDA designations, such as 510(k) or De Novo, contribute to a vendor’s verifiable record?
FDA designations provide a layer of regulatory validation for healthcare AI devices. While 510(k) clearance demonstrates substantial equivalence and doesn’t always require independent clinical validation, the De Novo pathway or Breakthrough Device Designation signal different levels of regulatory scrutiny and potential impact. These designations are part of the enduring record that analysts can check.
What is the significance of post-market surveillance programs in assessing healthcare AI vendors?
Post-market surveillance programs are crucial for understanding the long-term safety and effectiveness of AI devices. The article notes that a significant percentage of FDA-cleared AI devices have been recalled, with devices lacking published clinical evidence having a higher recall risk. The presence of such programs indicates a vendor’s commitment to ongoing monitoring and risk mitigation.